AbbVie Inc. (VIE:ABBV)

Austria flag Austria · Delayed Price · Currency is EUR
178.40
-14.00 (-7.28%)
At close: Feb 4, 2026
-2.50%
Market Cap337.61B +14.6%
Revenue (ttm)50.83B +7.4%
Net Income2.00B -53.4%
EPS1.13 -54.0%
Shares Outn/a
PE Ratio168.70
Forward PE17.18
Dividend5.75 (3.09%)
Ex-Dividend DateJan 16, 2026
Volumen/a
Average Volume11
Open191.40
Previous Close192.40
Day's Range177.60 - 192.40
52-Week Range149.00 - 207.50
Betan/a
RSI37.17
Earnings DateFeb 4, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Industry Biological Products, Except Diagnostic Substances
Founded 2012
Employees 55,000
Stock Exchange Vienna Stock Exchange
Ticker Symbol ABBV
Full Company Profile

Financial Performance

In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.23 billion, a decrease of -0.28%.

Financial numbers in USD Financial Statements